Copy to clipboard 
Safe Orthopaedics posted 3Q18 revenue of €0.8MM (~US $0.9MM), +20% vs. 3Q17, with YTD18 revenue of €2.4MM (~$2.8M), +7% vs. YTD17.
| 3Q18 | 3Q17 | $ Change | % Change | |
| Spine ($MM) | $0.9 | $0.8 | $0.2 | 20.0% |
| YTD18 | YTD17 | $ Change | % Change | |
| Spine ($MM) | $2.8 | $2.6 | $0.2 | 7.8% |
Sales by geographic region:
| 3Q18 | % Change | YTD18 | % Change | |
| France | $0.5 | 19.0% | $1.5 | 14.0% |
| Rest of World | $0.5 | 21.0% | $1.4 | -1.0% |
An increase in direct sales in France, Germany and the U.K. was the 3Q18 growth driver. These salesforces generated €512,000, +48% vs. the same period last year. Global distribution made headway in Europe (+28%) and Latin America (+148%), but lagged in the Middle East and Asia Pacific (-77%).
Territories in France were redefined to accommodate new 3Q18 sales hires, who started work in 4Q—with training on the SteriSpine VA Vertebral Augmentation system, which launched in late 3Q.
The U.K. salesforce, acquired from Qspine in 2Q, is now contributing in 2H18 as expected.
In Germany, the company appointed Mr. Holger Duerr as Head of Sales. Mr. Duerr has 12 years of kyphoplasty experience, having held sales and leadership positions at Dfine, Kyphon and Vexim.
Source: Safe Orthopaedics
Safe Orthopaedics posted 3Q18 revenue of €0.8MM (~US $0.9MM), +20% vs. 3Q17, with YTD18 revenue of €2.4MM (~$2.8M), +7% vs. YTD17.
Q18
Q17
$ Change
% Change
Spine ($MM)
$0.9
$0.8 ...
Safe Orthopaedics posted 3Q18 revenue of €0.8MM (~US $0.9MM), +20% vs. 3Q17, with YTD18 revenue of €2.4MM (~$2.8M), +7% vs. YTD17.
| 3Q18 | 3Q17 | $ Change | % Change | |
| Spine ($MM) | $0.9 | $0.8 | $0.2 | 20.0% |
| YTD18 | YTD17 | $ Change | % Change | |
| Spine ($MM) | $2.8 | $2.6 | $0.2 | 7.8% |
Sales by geographic region:
| 3Q18 | % Change | YTD18 | % Change | |
| France | $0.5 | 19.0% | $1.5 | 14.0% |
| Rest of World | $0.5 | 21.0% | $1.4 | -1.0% |
An increase in direct sales in France, Germany and the U.K. was the 3Q18 growth driver. These salesforces generated €512,000, +48% vs. the same period last year. Global distribution made headway in Europe (+28%) and Latin America (+148%), but lagged in the Middle East and Asia Pacific (-77%).
Territories in France were redefined to accommodate new 3Q18 sales hires, who started work in 4Q—with training on the SteriSpine VA Vertebral Augmentation system, which launched in late 3Q.
The U.K. salesforce, acquired from Qspine in 2Q, is now contributing in 2H18 as expected.
In Germany, the company appointed Mr. Holger Duerr as Head of Sales. Mr. Duerr has 12 years of kyphoplasty experience, having held sales and leadership positions at Dfine, Kyphon and Vexim.
Source: Safe Orthopaedics
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
